Inclusion Of Six-Year Overall Survival Data In The Eloxatin(R) (oxaliplatin Injection) Prescribing Information Granted FDA Priority Review

Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and assigned priority review status to a supplemental new drug application (sNDA) that proposes changes to the Eloxatin(R) (oxaliplatin injection) prescribing information (PI) to include a six-year analysis from the MOSAIC trial.

More: continued here

Filed under: Colorectal Cancer on February 26th, 2008